Literature DB >> 27075079

Cancer therapy: an evolved approach.

Cassandra Willyard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27075079     DOI: 10.1038/532166a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

1.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.

Authors:  Pedro M Enriquez-Navas; Yoonseok Kam; Tuhin Das; Sabrina Hassan; Ariosto Silva; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Sci Transl Med       Date:  2016-02-24       Impact factor: 17.956

2.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

Authors:  Hyo-eun C Bhang; David A Ruddy; Viveksagar Krishnamurthy Radhakrishna; Justina X Caushi; Rui Zhao; Matthew M Hims; Angad P Singh; Iris Kao; Daniel Rakiec; Pamela Shaw; Marissa Balak; Alina Raza; Elizabeth Ackley; Nicholas Keen; Michael R Schlabach; Michael Palmer; Rebecca J Leary; Derek Y Chiang; William R Sellers; Franziska Michor; Vesselina G Cooke; Joshua M Korn; Frank Stegmeier
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

3.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Authors:  Kang-Yi Su; Hsuan-Yu Chen; Ker-Chau Li; Min-Liang Kuo; James Chih-Hsin Yang; Wing-Kai Chan; Bing-Ching Ho; Gee-Chen Chang; Jin-Yuan Shih; Sung-Liang Yu; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Authors:  Ted W Johnson; Jeffrey A Engelman; Alice T Shaw; Luc Friboulet; Ignaty Leshchiner; Justin F Gainor; Simon Bergqvist; Alexei Brooun; Benjamin J Burke; Ya-Li Deng; Wei Liu; Leila Dardaei; Rosa L Frias; Kate R Schultz; Jennifer Logan; Leonard P James; Tod Smeal; Sergei Timofeevski; Ryohei Katayama; A John Iafrate; Long Le; Michele McTigue; Gad Getz
Journal:  N Engl J Med       Date:  2015-12-23       Impact factor: 91.245

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

7.  Evolutionary dynamics of cancer in response to targeted combination therapy.

Authors:  Ivana Bozic; Johannes G Reiter; Benjamin Allen; Tibor Antal; Krishnendu Chatterjee; Preya Shah; Yo Sup Moon; Amin Yaqubie; Nicole Kelly; Dung T Le; Evan J Lipson; Paul B Chapman; Luis A Diaz; Bert Vogelstein; Martin A Nowak
Journal:  Elife       Date:  2013-06-25       Impact factor: 8.140

8.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

Authors:  Sandra Misale; Ivana Bozic; Jingshan Tong; Ashley Peraza-Penton; Alice Lallo; Federica Baldi; Kevin H Lin; Mauro Truini; Livio Trusolino; Andrea Bertotti; Federica Di Nicolantonio; Martin A Nowak; Lin Zhang; Kris C Wood; Alberto Bardelli
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

9.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

  9 in total
  15 in total

Review 1.  Evolutionary scalpels for dissecting tumor ecosystems.

Authors:  Daniel I S Rosenbloom; Pablo G Camara; Tim Chu; Raul Rabadan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-05       Impact factor: 10.680

Review 2.  Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks.

Authors:  Angelo Fortunato; Amy Boddy; Diego Mallo; Athena Aktipis; Carlo C Maley; John W Pepper
Journal:  Cold Spring Harb Perspect Med       Date:  2017-02-01       Impact factor: 6.915

Review 3.  Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.

Authors:  Aleksandra Karolak; Dmitry A Markov; Lisa J McCawley; Katarzyna A Rejniak
Journal:  J R Soc Interface       Date:  2018-01       Impact factor: 4.118

4.  Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.

Authors:  Huang-Chiao Huang; Imran Rizvi; Joyce Liu; Sriram Anbil; Ashish Kalra; Helen Lee; Yan Baglo; Nancy Paz; Douglas Hayden; Steve Pereira; Brian W Pogue; Jonathan Fitzgerald; Tayyaba Hasan
Journal:  Cancer Res       Date:  2017-11-29       Impact factor: 12.701

5.  β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Authors:  Shanthi Ganesh; Xue Shui; Kevin P Craig; Martin L Koser; Girish R Chopda; Wendy A Cyr; Chengjung Lai; Henryk Dudek; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

6.  Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations.

Authors:  Gauri A Patwardhan; Michal Marczyk; Vikram B Wali; David F Stern; Lajos Pusztai; Christos Hatzis
Journal:  NPJ Breast Cancer       Date:  2021-05-26

Review 7.  Molecular chess? Hallmarks of anti-cancer drug resistance.

Authors:  Ian A Cree; Peter Charlton
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

Review 8.  Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Authors:  Albert A Antolin; Paul Workman; Jordi Mestres; Bissan Al-Lazikani
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

9.  Beyond dose: Pulsed antibiotic treatment schedules can maintain individual benefit while reducing resistance.

Authors:  Christopher M Baker; Matthew J Ferrari; Katriona Shea
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

Review 10.  The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.

Authors:  Yi-Chen Zhang; Qing Zhou; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2017-10-23       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.